#### Managing DARA Patient Testing and Transfusion Requests

|  |  |
| --- | --- |
| Purpose | Provide instructions for the management of blood product orders and testing for patients on Daratumumab/Darazalex (DARA) treatment protocol. |

|  |  |
| --- | --- |
| Policy | * When the physician orders a type and screen on a new multiple myeloma patient they will/should add a comment stating the patient is a potential candidate for DARA.
* Transfusion Service staff will order a phenotype on the patient from BloodSource reference laboratory; a genotype may be ordered if patient recently transfused.
* Enter a chartable comment (BBC) and PB (post to BAD file) in Sunquest. Result with ETC DARA (Anti- CD38. Patient receiving Daratumumab therapy.)
* DARA can take up to 6 months to clear the patient’s system so follow up inquiries by the laboratory are required to ensure the patient reactivity is due to the treatment.
 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Testing and Blood Product Orders  | Follow the steps below for a patient that has been identified as a potential candidate for DARA treatment or for patients reacting with all cells.

|  |  |
| --- | --- |
| Step | Action |
| 1 | If patent has not been previously identified as a DARA patient, call the patients nurse or physician to inquire whether the patient is currently on DARA, once the following test results are present (strength of reactivity is not relevant):

|  |  |
| --- | --- |
| Test … | Result… |
| Echo screen and panel and PEG screen | ALL positive |
| PEG screen and panel | ALL positive |
| Antibody Panel by any method | ALL positive  |

  |

  |

Continued on next page

Managing DARA Patient Testing and Transfusion Requests, Continued

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Testing and Blood Product Orders (continued) |

|  |  |
| --- | --- |
| Step | Action |
| 2 | Complete patient work up accordingly:

|  |  |
| --- | --- |
| If patient is… | Then… |
| Taking DARA or a History of Taking DARA | * No further work up is necessary.
* Enter a BBC with the following if provider is able to verify patient status:
* Verified patient taking DARA
* Name of person who verified the information
* Date and Time
* Enter a PB using the ETC “DARA”, if not already done.
* Send a sample to BloodSource for phenotyping or Blood Centers of Wisconsin for genotyping if patient has been recently transfused and phenotype has not been previously performed.
* Proceed to step 3.
 |
| NOT taking DARA or History Unknown | * Send a sample to BloodSource for further workup.
* Note on the BloodSource paperwork that patient is not taking DARA or history unknown.
 |

  |
| 3 | Order phenotypically negative units from BloodSource. |
| 4 | Perform an extended crossmatch using the Echo analyzer once units are received.NOTE: Least incompatible units will likely have to be given since DARA can interfere with the crossmatch as well; pathologist approval is not required for DARA patients. |

 |

Continued on next page

Managing DARA Patient Testing and Transfusion Requests, Continued

|  |  |
| --- | --- |
| Subsequent Workups | * Subsequent visits will not require full workup once you have reviewed your BAD file and verified the patient is on DARA.
* Antibody Screen only has to be tested using the Echo analyzer you are not required to run the ECHO panel and PEG screen again.
* Once screen is negative continue to provide phenotypically negative units until it has been confirmed with the patient’s physician they have permanently discontinued the DARA treatment.
 |